|Day Low/High||161.53 / 163.48|
|52 Wk Low/High||133.64 / 184.21|
Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.
Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.
Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.
The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.
It is the day when the White House launches the start of President Trump's tax reform.
U.S. stock futures are rising Wednesday as Wall Street awaits an announcement on tax cuts from the Trump administration.
You think the exchange is overvalued? I don't, and here's why.
Estimates for erenumab annual sales run as high as $2.3 billion.
Collaboration Designed to Maximize the Launch of First-in-Class Program and to More Effectively Reach People Living With Migraine
Corporate America shelled out big bucks for President Trump's inauguration.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Online News Resource Highlights Importance of Patient and Care Team Dialogue
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer sheds light on what's next for Amgen AMGN shares following its downgrade by Jefferies.
Jefferies lowered its rating on Amgen stock.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.
XGEVA is Currently Indicated for the Prevention of Skeletal-Related Events Known as Bone Complications in Patients With Solid Tumors
Preclinical Results for Mcl-1 Inhibitor for Multiple Myeloma Accepted as Oral Presentation